CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial With Addition of 7 More Clinical Sites

Sites in Europe and Asia add to patient enrollment and position Company to apply for global regulatory approvals December 8, 2014 CEL-SCI Corporation today announced that during November it has added seven new clinical sites to its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). Patient screening has begun at new clinical …

CEL-SCI Expands its Global Phase III Immunotherapy Head and Neck Cancer Trial into Centre Hospitalier Universitaire de Quebec in Canada

CHUQ is the latest medical center to join CEL-SCI’s trial in North America August 19th, 2014 CEL-SCI Corporation (NYSE MKT:CVM) today announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) has added Centre Hospitalier Universitaire de Québec (CHUQ)’s L’Hotel Dieu de Quebec to its growing number of clinical sites in North America. …

CEL-SCI Achieves Milestone in July with Total of 232 Patients Enrolled to Date in Its Phase III Head and Neck Cancer Trial

August 1st, 2014 –14 patients enrolled in July brings total enrollment to over one-quarter of the 880 patients planned for enrollment by the end of 2015 CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of July the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and …